OPKNasdaqPharmaceutical PreparationsFiscal year ends December 31
OPKO HEALTH, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Aug 28, 2026
$1.61+0.08 (+5.23%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
OPKO HEALTH, INC. revenue by segment
By business segment
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics [Member] | $55.14M | $32.22M | $21.26M | $17.87M | -$5.22M | -$13.64M | -$24.13M | -$44.70M | -$132.32M | -$150.00M | -$155.60M | -$136.46M | -1155.8% |
| Pharmaceutical [Member] | -$63.71M | -$93.26M | -$98.34M | -$89.76M | -$97.77M | -$93.88M | -$86.80M | -$100.72M | -$93.90M | -$5.45M | $41.18M | $35.23M | -34.8% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service [Member] | $313.06M | $339.62M | $370.28M | $402.30M | $428.33M | $456.62M | $480.67M | $501.73M | $512.14M | $509.80M | $515.28M | $530.47M | 53.3% | -26.9% |
| Product [Member] | $162.32M | $160.12M | $156.92M | $150.70M | $152.16M | $151.91M | $155.11M | $160.68M | $162.21M | $165.22M | $167.56M | $162.46M | 27.6% | +6.7% |
| Transfer of Intellectual Property and Other [Member] | $112.51M | $81.38M | $79.68M | $89.07M | $83.54M | $80.88M | $77.36M | $49.00M | $42.03M | $124.59M | $180.66M | $174.00M | 19.1% | +34.7% |
| Rayaldee [Member] | $58.82M | $59.08M | $59.39M | $62.37M | $63.36M | $67.25M | $69.30M | $69.05M | $69.28M | $68.42M | $67.55M | $64.14M | 10.0% | -7.2% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $377.28M | $403.36M | $436.06M | $477.89M | $499.63M | $526.47M | $546.30M | $545.26M | $551.64M | $544.78M | $597.82M | $611.44M | 64.2% | -24.5% |
| Ireland | $85.52M | $55.60M | $51.40M | $47.12M | $46.55M | $44.65M | $48.40M | $50.79M | $47.93M | $134.84M | $141.47M | $134.15M | 14.5% | +83.7% |
| Chile | $63.14M | $62.71M | $62.38M | $60.88M | $63.09M | $64.69M | $65.05M | $65.13M | $65.49M | $67.84M | $68.49M | $67.98M | 10.7% | +0.1% |
| Spain | $30.06M | $28.33M | $26.73M | $26.31M | $26.27M | $25.41M | $24.63M | $24.92M | $22.97M | $23.07M | $23.52M | $21.53M | 5.1% | +14.4% |
| Mexico | $26.98M | $26.23M | $25.52M | $24.51M | $23.40M | $23.01M | $23.87M | $21.39M | $21.66M | $21.47M | $20.22M | $20.30M | 4.6% | +15.3% |
| Other Countries [Member] | $4.60M | $4.43M | $4.27M | $4.04M | $3.70M | $3.49M | $3.12M | $2.77M | $2.58M | $2.30M | $2.25M | $1.96M | 0.8% | +24.4% |
| Israel | $311.00K | $450.00K | $522.00K | $1.33M | $1.38M | $1.69M | $1.77M | $1.15M | $4.11M | $5.30M | $9.74M | $9.57M | 0.1% | -77.5% |
From the segment and revenue-disaggregation notes of Opko Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.